RESEARCH MONOGRAPH · KDC-MN-187

Methylcobalamin

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

78/100

Active B12 form, real advantage in some contexts, mostly equivalent to cyanocobalamin if your methylation is working

Methylcobalamin is one of the two coenzyme forms of vitamin B12 (along with adenosylcobalamin), and it's the cofactor specifically used by methionine synthase (MTR) in the methylation cycle for converting homocysteine back to methionine. The other coenzyme form, adenosylcobalamin, is used by methylmalonyl-CoA mutase in mitochondrial branched-chain catabolism. So methyl and adenosyl B12 are not interchangeable in vivo, they're handled at different enzymes.

The supplement market positions methylcobalamin as the superior bioavailable form over cyanocobalamin, and the reality is more nuanced. Cyanocobalamin is a synthetic stable cobalamin that gets converted to the active coenzyme forms in vivo by intracellular enzymes (MMACHC handles the cyanide release, then the cobalt gets re-coordinated to methyl or adenosyl groups). Most healthy individuals do this conversion fine and the practical bioavailability difference is small.

The contexts where methylcobalamin specifically matters are: MTHFR/MTR variant carriers who have impaired methylation flux, smokers (where the additional cyanide load from cyanocobalamin is non-trivial at high doses), individuals with documented MMACHC or other cobalamin metabolism variants, and certain neurological conditions (especially diabetic neuropathy) where there's some clinical literature suggesting methylcobalamin has specific peripheral neuro-regenerative effects beyond what cyanocobalamin produces. The methylcobalamin neuropathy literature is mostly Japanese in origin and the effect sizes are real but modest.

For straightforward B12 deficiency correction, any cobalamin form works fine at adequate doses. The bigger variable is typically route (oral high-dose versus intramuscular versus sublingual) rather than form, and the parenteral route has clear pharmacokinetic advantages for severe deficiency.

Sourcing: methylcobalamin is more expensive than cyanocobalamin because the active coenzyme form is harder to synthesize and stabilize. HPLC verification is standard, and reputable suppliers produce consistent material. Hydroxocobalamin is the other clinically-relevant form often used parenterally with somewhat different pharmacokinetics.

Safety profile is exceptional, B12 has essentially no toxicity ceiling at supplemental doses.

What we like: it's the right form for specific genetic and clinical contexts, and the diabetic neuropathy signal is interesting. What we dont like: the marketing implies methylcobalamin is uniformly superior to cyanocobalamin when for most users with intact methylation it really isnt, and the price difference is meaningful.

Evidence: 70
Mechanism: 88
Reliability: 78
Safety: 92
Sourcing: 80
Value: 70
Signal: 65
Staying power: 78

Plain-language summary Intrigue 50 / 100

Methylcobalamin is the active methyl-bound form of vitamin B12. Used preferentially over cyanocobalamin (which the body has to convert) for B12 deficiency, neuropathy, and methylation support. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Active vitamin B12

The active methyl-form of vitamin B12 used for methylation support, particularly in subjects with cobalamin metabolism polymorphisms.

Abstract

Methylcobalamin is the active methyl-form of vitamin B12 (cobalamin), one of two coenzyme forms (the other being adenosylcobalamin). The compound is the cofactor for methionine synthase, which transfers methyl groups from 5-methyltetrahydrofolate to homocysteine to produce methionine and tetrahydrofolate. Methylcobalamin supplementation provides directly active B12 without requiring conversion from cyanocobalamin (the synthetic form most commonly used in supplementation), bypassing potential metabolic limitations. Reported research dose ranges in the literature are described in the source publications. sublingual or injectable forms have higher bioavailability than oral.

Mechanism of action

Active B12 cofactor for methionine synthase; supports methylation cycle.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Stabler SP. Vitamin B12 deficiency. N Engl J Med 2013.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-187

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Methylcobalamin

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs